A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man at least 18 years old with prostate cancer that has spread to other parts of the body.
- Your cancer must have gotten worse despite having low testosterone levels (from surgery or medication) and after taking a hormone therapy pill like abiraterone or enzalutamide for at least 12 weeks.
- You must have a PET scan showing your cancer cells have a protein called PSMA, which the study drug can target.
- You need to be in fairly good health, able to care for yourself, and have adequate blood cell counts, kidney, and liver function.
- You cannot have had certain prior treatments like chemotherapy for advanced disease, other radioactive therapies, or a prior PSMA-targeted drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.